BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12697967)

  • 1. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer.
    Wang C; van Rijnsoever M; Grieu F; Bydder S; Elsaleh H; Joseph D; Harvey J; Iacopetta B
    Oncology; 2003; 64(3):259-65. PubMed ID: 12697967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW
    Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
    Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability and colorectal cancer prognosis.
    Benatti P; GafĂ  R; Barana D; Marino M; Scarselli A; Pedroni M; Maestri I; Guerzoni L; Roncucci L; Menigatti M; Roncari B; Maffei S; Rossi G; Ponti G; Santini A; Losi L; Di Gregorio C; Oliani C; Ponz de Leon M; Lanza G
    Clin Cancer Res; 2005 Dec; 11(23):8332-40. PubMed ID: 16322293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive significance of microsatellite instability in stage II colorectal carcinoma: An 8-year study from a tertiary center in South India.
    Paulose RR; Ail DA; Biradar S; Vasudevan A; Sundaram KR
    Indian J Cancer; 2019; 56(4):302-308. PubMed ID: 31607697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.
    Rosty C; Chazal M; Etienne MC; Letoublon C; Bourgeon A; Delpero JR; Pezet D; Beaune P; Laurent-Puig P; Milano G
    Int J Cancer; 2001 May; 95(3):162-7. PubMed ID: 11307149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
    Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
    Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer.
    Wright CM; Dent OF; Barker M; Newland RC; Chapuis PH; Bokey EL; Young JP; Leggett BA; Jass JR; Macdonald GA
    Br J Surg; 2000 Sep; 87(9):1197-202. PubMed ID: 10971428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.
    Halling KC; French AJ; McDonnell SK; Burgart LJ; Schaid DJ; Peterson BJ; Moon-Tasson L; Mahoney MR; Sargent DJ; O'Connell MJ; Witzig TE; Farr GH; Goldberg RM; Thibodeau SN
    J Natl Cancer Inst; 1999 Aug; 91(15):1295-303. PubMed ID: 10433618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.